Aidoc, a startup that developed a clinical AI solution that leverages foundational models, has secured a $150 million funding round, less than a year after raising the same nine-figure amount in new funding.
The Series E round was led by Goldman Sachs Alternatives Growth Equity with participation from General Catalyst, SoftBank Vision Fund 2, and NVentures, the venture capital arm of NVIDIA.
This round brings the company’s total funding to more than $500 million, less than a year after a growth round led by General Catalyst and Square Peg. Aidoc executives noted that this highlights the company’s pace of momentum and “accelerating demand for enterprise-scale clinical AI.”
Diagnostic errors and delays account for at least 400,000 deaths each year in the United States due to increased imaging volume, workforce shortages, and increased clinical complexity.
Hospitals are now looking for broader system-wide solutions and clinical AI that can be deployed across the healthcare system.
Aidoc has developed a clinical infrastructure model called CARE (Clinical AI Reasoning Engine) to support physicians’ clinical decision-making. Earlier this year, CARE received FDA clearance for the first time for a comprehensive two-digit fundamental model-based triage system in clinical imaging. The company analyzes more than 60 million patient cases annually and is deployed in approximately 2,000 hospitals. Aidoc has also developed Aidoc aiOS, an enterprise AI platform that embeds AI directly into clinical workflows. This allows health systems to deploy, manage, and scale multiple FDA-cleared solutions through a centralized operating layer.
“By 2030, all complex diagnostic decisions will be supported by AI, enabling early detection and reducing avoidable errors,” Aidoc co-founder and CEO Elad Wallach said in a statement. “We feel a deep commitment to deploying CARE safely and at scale across the health system. This funding will accelerate comprehensive disease coverage and advance end-to-end AI across CT and X-ray, extending across workflows from pixels to draft reports within two years.”
With the new capital, Aidoc plans to expand its CARE-based model and expand into additional clinical indications. “Comprehensive coverage of major clinically important conditions, both acute and chronic, throughout the body with CT and X-ray, including automated detection, measurement and comparison,” Walach told Fierce Healthcare.
Last year, the company expanded its clinical AI solutions into oncology and cardiovascular disease to help clinicians with decision-making and diagnosis. The company also received Food and Drug Administration clearance for its CADt AI solution in February 2025. This approval applied to Aidoc’s rib fracture triage solution.
The company also plans to build new capabilities such as automated image draft reporting to enhance end-to-end clinical AI workflows.
As clinical AI moves into enterprise deployments, hospitals are also looking to consolidate standalone tools under a centralized operational framework to more efficiently manage and manage AI at scale, which the company says will drive adoption of its aiOS Enterprise AI platform.
Scaling AI technologies in complex healthcare systems also requires oversight and accountability to operate safely in real-world healthcare.
“Idoc combines advanced technology with strict regulation in a way that few companies have been able to achieve before,” Christian Resch, growth equity partner at Goldman Sachs Alternatives, said in a statement. “Health systems consistently describe tangible outcomes such as improved radiology efficiency, reduced length of stay, and measurable economic benefits. We believe this combination of innovation, safety, technical rigor, and operational discipline will position Aidoc as a long-term leader in clinical AI.”
